✦ LIBER ✦

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

✍ Scribed by Nubia Muñoz; Ricardo Manalastas Jr; Punee Pitisuttithum; Damrong Tresukosol; Joseph Monsonego; Kevin Ault; Christine Clavel; Joaquin Luna; Evan Myers; Sara Hood; Oliver Bautista; Janine Bryan; Frank J Taddeo; Mark T Esser; Scott Vuocolo; Richard M Haupt; Eliav Barr; Alfred Saah

Book ID: 117304699
Publisher: The Lancet
Year: 2009
Tongue: English
Weight: 171 KB
Volume: 373
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(09)60691-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety, immunogenicity, and efficacy of

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women

✍ Gonzalo Perez; Eduardo Lazcano-Ponce; Mauricio Hernandez-Avila; Patricia J. Garc 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 103 KB

## Abstract The prevalence of HPV infection in Latin America is among the highest in the world. A quadrivalent (types 6/11/16/18) human papillomavirus L1 virus‐like‐particle vaccine has been shown to be 95–100% effective in preventing HPV 6/11/16/18‐related cervical and genital disease in women naï

Prophylactic quadrivalent human papillom

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

✍ Luisa L Villa; Ronaldo LR Costa; Carlos A Petta; Rosires P Andrade; Kevin A Ault 📂 Article 📅 2005 🏛 The Lancet 🌐 English ⚖ 109 KB

The impact of a quadrivalent human papil

The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24

✍ S Majewski; FX Bosch; J. Dillner; O-E Iversen; SK Kjaer; N Muñoz; S-E Olsson; J 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB

Safety and immunogenicity of a vaccine t

Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, double-blind, placebo-controlled trial in Chinese males and females

✍ Rongcheng Li; Yanping Li; David Radley; Youping Liu; Teng Huang; Heather L. Sing 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 350 KB

Safety and immunogenicity of a vaccine t

Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects

✍ S. KANG; K.H. KIM; Y.T. KIM; Y.T. KIM; J.H. KIM; Y.S. SONG; S.H. SHIN; H.S. RYU; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB

Efficacy of a quadrivalent prophylactic

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

✍ Elmar A Joura; Sepp Leodolter; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonz 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 165 KB